동종 조혈모세포 이식환자에서 Pentoxifylline의 간정맥폐쇄성 질환 예방효과
Prevention of Hepatic Veno-Occlusive Disease with Pentoxifylline after Allogeneic Hematopoietic Stem Cell Transplantation
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background : Veno-occlusive disease (VOD) is a potentially devastating complication that can develop after hematopoietic stem cell transplantation (HSCT). The incidence is higher for allogeneic than autologous HSCT. Previous studies on the prevention of VOD with pentoxifylline have limitations to apply for the present state due to the difference of VOD criteria. This study examines the effectiveness of pentoxifylline in preventing VOD according to current diagnostic criteria for a patient with allogeneic HSCT. Methods : Allogeneic HSCT recipients from 2013 to 2018 were selected for this retrospective analysis. Subjects were divided into three groups depending on pentoxifylline administration. The first and the second group took pentoxifylline for more than two weeks and for less than two weeks respectively, while the last group did not take it. The primary endpoints were the incidence rates of VOD. Secondary endpoints were hyperbilirubinemia (≥2 mg/dL), weight gain ( 5% of baseline), painful hepatomegaly, ascites, and taking VOD treatment (defibrotide) or liver function agent. Results : 210 patients were included. The incidence rate of VOD was 5.0% in the first group vs. 6.5% in the second group vs. 6.5% in the last group (p=0.779). There was no significantly difference in hyperbilirubinemia (p=0.844), weight gain (p=0.292), painful hepatomegaly (p=0.093), ascites (p=0.912), taking defibrotide (p=0.886), taking liver function agent (p=0.508). Conclusions : This study confirmed that there is no VOD prevention effect of pentoxifylline in patients with allogeneic HSCT. Further studies are needed to develop more effectiveness prophylactic approaches of VOD.
Abstract
Background : Veno-occlusive disease (VOD) is a potentially devastating complication that can develop after hematopoietic stem cell transplantation (HSCT). The incidence is higher for allogeneic than autologous HSCT. Previous studies on the prevention of VOD with pentoxifylline have limitations to apply for the present state due to the difference of VOD criteria. This study examines the effectiveness of pentoxifylline in preventing VOD according to current diagnostic criteria for a patient with allogeneic HSCT. Methods : Allogeneic HSCT recipients from 2013 to 2018 were selected for this retrospective analysis. Subjects were divided into three groups depending on pentoxifylline administration. The first and the second group took pentoxifylline for more than two weeks and for less than two weeks respectively, while the last group did not take it. The primary endpoints were the incidence rates of VOD. Secondary endpoints were hyperbilirubinemia (≥2 mg/dL), weight gain ( 5% of baseline), painful hepatomegaly, ascites, and taking VOD treatment (defibrotide) or liver function agent. Results : 210 patients were included. The incidence rate of VOD was 5.0% in the first group vs. 6.5% in the second group vs. 6.5% in the last group (p=0.779). There was no significantly difference in hyperbilirubinemia (p=0.844), weight gain (p=0.292), painful hepatomegaly (p=0.093), ascites (p=0.912), taking defibrotide (p=0.886), taking liver function agent (p=0.508). Conclusions : This study confirmed that there is no VOD prevention effect of pentoxifylline in patients with allogeneic HSCT. Further studies are needed to develop more effectiveness prophylactic approaches of VOD.
참고문헌 (17)
- Mohty M, "Revised diagnosis and severity criteria for sinusoidal obstruction syndrome", venoocclusive disease in adult patients : a new classification from the European Society for Blood and Marrow Transplantation, 2016, pp.51(7), 906~912
- Holler E, "Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation", Blood, 75(4), pp.1011~1016 (1990)
- Bianco JA, "Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation", Blood, 78(5), pp.1205~1211 (1991)
- Tilg H, "Immune response modulation by pentoxifylline in vitro", Transplantation, 56(1), pp.196~201 (1993)
- Strieter RM, "Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline", Biochem Biophys Res Commun, 155(3), pp.1230~1236 (1988)
- Harold R., "Clinical Pharmacology of Pentoxifylline With Special Reference to Its Hemorrheologic Effect for the Treatment of Intermittent Claudication", The Journal of Clinical Pharmacology, 25(1), pp.8~26 (1985)
- Reich T, "Pentoxifylline in the Treatment of Intermittent Claudication of the Lower Limbs", Angiology, 35(7), pp.389~395 (1984)
- Attal M, "Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline : a prospective, randomized trial", Blood, 82(3), pp.732~736 (1993)
- Clift RA, "A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation", Blood, 82(7), pp.2025~2030 (1993)
- Ferra C, "Pentoxifylline, ciprofloxacin and prednisone failed to prevent transplant-related toxicities in bone marrow transplant recipients and were associated with an increased incidence of infectious complications", Bone Marrow Transplant, 20(12), pp.1075~1080 (1997)
- Kalhs P, "Pentoxifylline did not prevent transplantrelated toxicity in 31 consecutive allogeneic bone marrow transplant recipients", Blood, 80(10), pp.2683~2684 (1992)
- Lee S, "Hepatic Veno-occlusive disease after allogeneic bone marrow transplantation in patients with leukemia : risk factors and therapeutic effect of recombinant human tissue plasminogen activator", Ewha Med, 22(2), pp.281~289 (1999)
- Dignan FL, "BCSH", BSBMT guideline : diagnosis and management of veno-occlusive disease(sinusoidal obstruction syndrome)following haematopoietic stem cell transplantation, 2013, pp.163(4), 444~457
- Parikh PM, "Serum tumor necrosis factor for monitoring response of hepatic veno-occlusive disease to pentoxiphyllin-a case report", Cancer Invest, 15(4), pp.326~328 (1997)
- Lassau N, "Hepatic veno-occlusive disease after myeloablative treatment and bone marrow transplantation : value of gray-scale and Doppler US in 100 patients", Radiology, 204(2), pp.545~552 (1997)
- Mahgerefteh SY, "Radiologic imaging and intervention for gastrointestinal and hepatic complications of hematopoietic stem cell transplantation", Radiology, 258(3), pp.660~671 (2011)
- Mohty M, "Sinusoidal obstruction syndrome", venoocclusive disease : current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation(EBMT), 2015, pp.50(6), 781~789